Focused Ultrasound for Behavioral Health
Eligible age
22–80 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a double-blind, within-participant crossover, multi-site dose-finding study evaluating the safety, feasibility, and preliminary efficacy of repeated low-intensity focused ultrasound (LIFU) stimulation using the ATTN201 device across seven candidate deep-brain targets in adults with subsyndromal-to-moderate depression, anxiety, or obsessive-compulsive disorder. Every session delivers active ATTN201 stimulation; there is no sham or placebo condition. Participants and the on-site study staff who deliver stimulation and administer the clinical scales are blinded to the brain target and to the stimulation parameters assigned for each session by a constrained Bayesian optimization algorithm.
Sponsor: Attune Neurosciences Inc
You may qualify if…
- ✓ Be between 22 and 80 years of age (inclusive) on the day of signing informed consent.
- ✓ Have at least one of the following at screening: PHQ-9 total score 5-16 (depression), GAD-7 total score 5-14 (anxiety), or OCI-R total score 14-27 (obsessive-compulsive disorder).
- ✓ If currently taking psychiatric medication, have been on the same stable dose(s) for at least 4 weeks prior to screening and be willing to maintain the regimen throughout the treatment period.
- ✓ Be able and willing to undergo a multi-sequence cranial MRI.
- ✓ Be willing to use the ATTN201 device during stimulation visits and to attempt use of monitoring devices (optional ambulatory EEG system, smart watch) during the pre- and post-stimulation monitoring blocks; use of the optional ambulatory EEG system does not affect eligibility.
- ✓ Sign the informed consent form, in accordance with local requirements, after the scope and nature of the investigation have been explained to the participant, and before any screening assessments.
- ✓ Be able to speak, read, and understand English.
- ✓ Be able to use a smartphone and the Attune platform.
You may not qualify if…
- ✕ Columbia Suicide Severity Rating Scale (C-SSRS) score ≥ 3 (ideation with intent, with or without plan) at screening.
- ✕ Any suicide attempt within the past 12 months.
- ✕ Any change in psychiatric medication (start, stop, or dose change) within 4 weeks prior to screening.
- ✕ Has an unstable or severe medical or psychiatric condition that, in the investigator's judgment, would pose a safety risk to the participant or prevent completion of study procedures. Stable comorbid conditions (e.g., treated depression, anxiety, OCD, insomnia) within the protocol-specified score windows are permitted.
- ✕ Has an active, unstable substance use disorder including alcohol use disorder in the past 6 months (except for caffeine and nicotine). Participants on stable medication-assisted treatment (e.g., buprenorphine, methadone, naltrexone) for at least 6 months are eligible.
- ✕ Has a history of moderate-to-severe traumatic brain injury, or mild traumatic brain injury within the past 12 months.
- ✕ Has a history of seizure disorder or epilepsy, or any structural CNS lesion known to lower seizure threshold.
- ✕ Has any contraindications for completing a brain MRI scan (e.g., pacemaker, ferromagnetic implants).
Where it's recruiting
San Francisco
Source: ClinicalTrials.gov · NCT07851038 · last updated 2026-10-27